Win-win cooperation for advancing medical innovation

The Innovation Medicine Pub Date : 1900-01-01 DOI:10.59717/j.xinn-med.2023.100002

Jie Qiao

{"title":"Win-win cooperation for advancing medical innovation","authors":"Jie Qiao","doi":"10.59717/j.xinn-med.2023.100002","DOIUrl":null,"url":null,"abstract":"Peking University Health Science Center, Beijing 100191, China *Correspondence: Jie Qiao: jie.qiao@263.net Received: May 5, 2023; Accepted: May 29, 2023; Published Online: June 6, 2023; https://doi.org/10.59717/j.xinn-med.2023.100002 © 2023 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Citation: Qiao J. (2023). Win-win cooperation for advancing medical innovation. The Innovation Medicine 1(1), 100002. Scientific and technological advancements in medicine have always been highly esteemed worldwide. According to statistics published by the Organization for Economic Cooperation and Development (OECD), global health spending accounted for 9.6% of GDP in 2021. Research and development expenses incurred in “health and environmental projects” comprised 30% to 50% of the total R&D funds available in major developed countries such as the United States and the United Kingdom in 2019. . Novel scientific and technological advancements in medicine will be key areas for innovation and capital investments globally over the next 30 years. These medical innovations are expected to generate new preventative, diagnostic, and treatment methods, as well as health monitoring techniques, new drugs, and devices for managing diseases. These advancements in medicine will not only accelerate existing medical and commercial processes to address people’s ever-changing health demands but also enhance the ability to respond effectively to future emergencies, such as pandemics. Ultimately, the benefits will extend to the entire global community. Achieving this goal requires global cooperation across all levels: governments, medical companies, hospitals, and scientific research institutes must collaborate to create a favorable ecosystem for medical innovation. Governments and companies must partner to tackle the critical challenge of ensuring that innovative products benefit as many individuals as possible.","PeriodicalId":423184,"journal":{"name":"The Innovation Medicine","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Innovation Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.59717/j.xinn-med.2023.100002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Peking University Health Science Center, Beijing 100191, China *Correspondence: Jie Qiao: jie.qiao@263.net Received: May 5, 2023; Accepted: May 29, 2023; Published Online: June 6, 2023; https://doi.org/10.59717/j.xinn-med.2023.100002 © 2023 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Citation: Qiao J. (2023). Win-win cooperation for advancing medical innovation. The Innovation Medicine 1(1), 100002. Scientific and technological advancements in medicine have always been highly esteemed worldwide. According to statistics published by the Organization for Economic Cooperation and Development (OECD), global health spending accounted for 9.6% of GDP in 2021. Research and development expenses incurred in “health and environmental projects” comprised 30% to 50% of the total R&D funds available in major developed countries such as the United States and the United Kingdom in 2019. . Novel scientific and technological advancements in medicine will be key areas for innovation and capital investments globally over the next 30 years. These medical innovations are expected to generate new preventative, diagnostic, and treatment methods, as well as health monitoring techniques, new drugs, and devices for managing diseases. These advancements in medicine will not only accelerate existing medical and commercial processes to address people’s ever-changing health demands but also enhance the ability to respond effectively to future emergencies, such as pandemics. Ultimately, the benefits will extend to the entire global community. Achieving this goal requires global cooperation across all levels: governments, medical companies, hospitals, and scientific research institutes must collaborate to create a favorable ecosystem for medical innovation. Governments and companies must partner to tackle the critical challenge of ensuring that innovative products benefit as many individuals as possible.

查看原文本刊更多论文

合作共赢，推进医疗创新

北京大学医学部，北京100191 *通讯:乔杰:jie.qiao@263.net收稿日期:2023年5月5日;录用日期:2023年5月29日;在线出版:2023年6月6日;https://doi.org/10.59717/j.xinn-med.2023.100002©2023作者。这是一篇基于CC BY-NC-ND许可(http://creativecommons.org/licenses/by-nc-nd/4.0/)的开放获取文章。引用本文:乔杰(2023)。合作共赢，推进医疗创新。创新医学1(1)，2000。医学方面的科技进步一直受到全世界的高度重视。根据经济合作与发展组织(OECD)公布的统计数据，2021年全球卫生支出占GDP的9.6%。2019年，在美国、英国等主要发达国家，“健康和环境项目”的研发费用占可用研发资金总额的30%至50%。医药领域的新科技进步将是未来30年全球创新和资本投资的关键领域。这些医学创新有望产生新的预防、诊断和治疗方法，以及健康监测技术、新药和管理疾病的设备。医学上的这些进步不仅将加速现有的医疗和商业进程，以满足人们不断变化的健康需求，而且还将增强有效应对未来突发事件(如流行病)的能力。最终，这些好处将惠及整个全球社会。实现这一目标需要全球各级合作:政府、医疗公司、医院和科研机构必须合作，为医疗创新创造有利的生态系统。政府和公司必须合作，以应对确保创新产品使尽可能多的人受益的关键挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Innovation Medicine

自引率

0.00%

发文量